The co-inhibitory immune checkpoint proteins B7-H1(PD-L1) and B7-H4 in high grade glioma: From bench to bedside

被引:2
作者
Qi, Ying [1 ,2 ,3 ,4 ,5 ]
Huang, Xiaoming [1 ,2 ,3 ,4 ,5 ]
Ji, Chunxia [1 ,2 ,3 ,4 ,5 ]
Wang, Chaojun [6 ]
Yao, Yu [1 ,2 ,3 ,4 ,5 ]
机构
[1] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Neurosurg, Shanghai, Peoples R China
[2] Natl Ctr Neurol Disorders, Shanghai, Peoples R China
[3] Shanghai Key Lab Brain Funct & Restorat & Neural R, Shanghai, Peoples R China
[4] Fudan Univ, Immunol Lab, Neurosurg Inst, Shanghai, Peoples R China
[5] Shanghai Clin Med Ctr Neurosurg, Shanghai, Peoples R China
[6] MSD China Holding Co Ltd, Shanghai, Peoples R China
基金
国家重点研发计划;
关键词
PD-L1; Glioma; Immunotherapy; Immune checkpoint; B7; FAMILY-MEMBER; T-CELL; TUMOR-CELLS; IMMUNOGENIC MODULATION; MACROPHAGES; LYMPHOCYTES; BLOCKADE; MOUSE;
D O I
10.1016/j.tranon.2023.101793
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Co-inhibitory immune checkpoints play a crucial role in tumor progression, and PD-1/PD-L1 inhibitor has been a breakthrough for treating multiple refractory tumors in last decade. Nevertheless, results of several phase III clinical trials of PD-1/PD-L1 inhibitor are unsatisfactory in high grade gliomas recently. This article reviews the promising biomarkers which can predict the efficacy of PD-1/PD-L1 blockade immunotherapy and current status of emerging strategies involving PD-1/PD-L1 inhibitors, especially the combination treatment and neoadjuvant PD-1 therapy in gliomas. In addition, B7-H4, one of the most promising immune checkpoints, is also briefly reviewed here for its clinical significance, regulatory mechanism and developing immunotherapeutic strategies in pre-clinical glioma models.
引用
收藏
页数:11
相关论文
共 69 条
[1]  
Baldini C, 2022, NEURO-ONCOLOGY, V24, P59
[2]   DNA mismatch repair in cancer [J].
Baretti, Marina ;
Le, Dung T. .
PHARMACOLOGY & THERAPEUTICS, 2018, 189 :45-62
[3]  
Bast Jr Robert C., 2023, Holland-Frei Cancer Medicine, V61
[4]   Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome? [J].
Berghoff, Anna S. ;
Preusser, Matthias .
NATURE REVIEWS NEUROLOGY, 2019, 15 (06) :314-315
[5]   Therapeutic and prognostic insights from the analysis of cancer mutational signatures [J].
Brady, Samuel W. ;
Gout, Alexander M. ;
Zhang, Jinghui .
TRENDS IN GENETICS, 2022, 38 (02) :194-208
[6]   Implementing TMB measurement in clinical practice: considerations on assay requirements [J].
Buettner, Reinhard ;
Longshore, John W. ;
Lopez-Rios, Fernando ;
Merkelbach-Bruse, Sabine ;
Normanno, Nicola ;
Rouleau, Etienne ;
Penault-Llorca, Frederique .
ESMO OPEN, 2019, 4 (01)
[7]   Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1 [J].
Chamoto, Kenji ;
Yaguchi, Tomonori ;
Tajima, Masaki ;
Honjo, Tasuku .
NATURE REVIEWS IMMUNOLOGY, 2023, 23 (10) :682-695
[8]  
Chen D, 2020, J Immunother Cancer, V8
[9]   The Prognostic and Therapeutic Value of PD-L1 in Gliomaa [J].
Chen, Ruo Qiao ;
Liu, Feng ;
Qiu, Xin Yao ;
Chen, Xiao Qian .
FRONTIERS IN PHARMACOLOGY, 2019, 9
[10]   Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [J].
Cloughesy, Timothy F. ;
Mochizuki, Aaron Y. ;
Orpilla, Joey R. ;
Hugo, Willy ;
Lee, Alexander H. ;
Davidson, Tom B. ;
Wang, Anthony C. ;
Ellingson, Benjamin M. ;
Rytlewski, Julie A. ;
Sanders, Catherine M. ;
Kawaguchi, Eric S. ;
Du, Lin ;
Li, Gang ;
Yong, William H. ;
Gaffey, Sarah C. ;
Cohen, Adam L. ;
Mellinghoff, Ingo K. ;
Lee, Eudocia Q. ;
Reardon, David A. ;
O'Brien, Barbara J. ;
Butowski, Nicholas A. ;
Nghiemphu, Phioanh L. ;
Clarke, Jennifer L. ;
Arrillaga-Romany, Isabel C. ;
Colman, Howard ;
Kaley, Thomas J. ;
De Groot, John F. ;
Liau, Linda M. ;
Wen, Patrick Y. ;
Prins, Robert M. .
NATURE MEDICINE, 2019, 25 (03) :477-+